Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + abemaciclib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Fulvestrant + abemaciclib is a combination therapy used for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer in women with disease progression after endocrine therapy. Abemaciclib is a CDK4/6 inhibitor with greater relative potency for cyclin D1/CDK4 compared with cyclin D3/CDK6. Fulvestrant is an estrogen receptor antagonist. The combination has demonstrated significant improvement in progression-free survival compared to fulvestrant alone.
02
Targets
CDK6 (Cyclin-dependent kinase 6)ESR2 (ERβ)CDK4 (Cyclin-dependent kinase 4)ESR1 (ERα)
Beyond the preview
Go deeper on fulvestrant + abemaciclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + abemaciclib.